Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hellmann

Showing results (151-160 of 235) with videos related to

Pageof 24
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionE J Aguilar, B Ricciuti, J F Gainor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung CancerAdam J Schoenfeld, Hira A Rizvi, Danish Memon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
The Journal of Experimental Medicine|December 22, 2021
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasionMojdeh Shakiba, Paul Zumbo, Gabriel Espinosa-Carrasco, et al.
The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumorsM D Hellmann, T-W Kim, C B Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2020
The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung CancerAdam J Schoenfeld, Chai Bandlamudi, Jessica A Lavery, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysisH Borghaei, T-E Ciuleanu, J-S Lee, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRamaswamy Govindan, Charu Aggarwal, Scott J Antonia, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Pageof 24

Showing results (151-160 of 235) with videos related to

Sort By:
Pageof 24
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionE J Aguilar, B Ricciuti, J F Gainor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung CancerAdam J Schoenfeld, Hira A Rizvi, Danish Memon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
The Journal of Experimental Medicine|December 22, 2021
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasionMojdeh Shakiba, Paul Zumbo, Gabriel Espinosa-Carrasco, et al.
The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumorsM D Hellmann, T-W Kim, C B Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2020
The Genomic Landscape of <i>SMARCA4</i> Alterations and Associations with Outcomes in Patients with Lung CancerAdam J Schoenfeld, Chai Bandlamudi, Jessica A Lavery, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysisH Borghaei, T-E Ciuleanu, J-S Lee, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesotheliomaRamaswamy Govindan, Charu Aggarwal, Scott J Antonia, et al.
JCO Precision Oncology|December 14, 2019
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung CancerNatalie I Vokes, David Liu, Biagio Ricciuti, et al.
Pageof 24